Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 open-label drug-drug interaction study of encorafenib + binimetinib in BRAF V600-mutant advanced solid tumors
NL-OMON55423Phase 1Completed
- Sponsor
- Array BioPharma
- Start
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of encorafenib and binimetinib in melanoma, colorectal cancer (CRC), biliary cancer and 5 more (3 arms), sponsored by Array BioPharma. Primary endpoints: Change in plasma Cmax and AUClast of probe substrates and metabolites, Change in urinary Ae0-8 of losartan and dextromethorphan pathways and 1 more. Started Nov 2020; status: completed.
02
Drugs
encorafenibbinimetinib
03
Conditions
melanomacolorectal cancer (CRC)biliary cancernon-small cell lung cancer (NSCLC)glioblastoma (GBM)
Beyond the preview
Go deeper on NL-OMON55423.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55423.